HC Wainwright Reiterates Buy Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

HC Wainwright restated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI - Free Report) in a research report released on Wednesday,Benzinga reports. The firm currently has a $7.00 price target on the stock.

A number of other analysts have also commented on the company. StockNews.com lowered Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. Piper Sandler boosted their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $5.00.

Karyopharm Therapeutics Stock Up 0.4 %

KPTI traded up $0.00 during trading on Wednesday, reaching $0.64. 493,779 shares of the stock traded hands, compared to its average volume of 888,532. The stock's 50-day moving average is $0.76 and its 200 day moving average is $0.81. Karyopharm Therapeutics has a 12 month low of $0.58 and a 12 month high of $1.95. The stock has a market capitalization of $80.22 million, a PE ratio of -0.56 and a beta of 0.07.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to analyst estimates of $37.86 million. During the same period last year, the firm posted ($0.30) earnings per share. As a group, equities research analysts anticipate that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KPTI. Point72 DIFC Ltd bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $143,000. Acadian Asset Management LLC bought a new position in Karyopharm Therapeutics during the 2nd quarter valued at $167,000. Exchange Traded Concepts LLC lifted its stake in Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock valued at $182,000 after acquiring an additional 56,613 shares in the last quarter. Finally, FMR LLC boosted its holdings in Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company's stock worth $307,000 after acquiring an additional 76,510 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).